https://multiplesclerosisnewstoday.com/2017/05/02/ms-remyelination-therapy-opicinumab-fails-phase2-trial-biogen-wont-give-up/
MS Remyelination Therapy Opicinumab Fails in Phase 2 Trial, But Biogen Won't Give Up
Feb 12, 2024 - Read about how a failed trial is not the end for the MS remyelination agent opicinumab, as researchers observed disability improvements in certain groups.
in phasegive upremyelinationtherapyopicinumab